Skip to main content
SpringerLink
Log in

Diseases with Underlining Internal Conditions

  • Chapter
  • First Online:
Practical Immunodermatology

  • 916 Accesses

Abstract

The specific dermatoses of pregnancy are defined as a group of pruritic inflammatory dermatoses associated exclusively with pregnancy and/or the immediate postpartum period [1]. Classification of this disease entity remains a topic of debate. The three generally accepted dermatoses include pemphigoid gestationis (PG), polymorphic eruption of pregnancy (PEP), and intrahepatic cholestasis of pregnancy (ICP) [2]. Apart from these three, a series of clinical entities in pregnancy have been previously documented including prurigo of pregnancy, pruritic folliculitis of pregnancy, and atopic dermatitis. However, recent literature has illustrated significant overlaps in clinical presentation and histopathology between these three presentations and, therefore, they will all be categorized together under the term “atopic eruption of pregnancy” (AEP) [3]. It is important to note that two of these four dermatoses (PG and ICP) may pose significant risk for the fetus, and that early recognition and appropriate diagnostic testing are imperative. This chapter will focus on diagnosis, pathogenesis, and management of the four aforementioned dermatoses of pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

Dermatoses of Pregnancy

  1. Ambros-Rudolph CM. Dermatoses of pregnancy. J Dtsch Dermatol Ges. 2006;4(9):748–59; quiz 760–1.

    Article  PubMed  Google Scholar 

  2. Lehrhoff S, Pomeranz MK. Specific dermatoses of pregnancy and their treatment. Dermatol Ther. 2013;26(4):274–84.

    Article  PubMed  Google Scholar 

  3. Ambros-Rudolph CM, et al. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol. 2006;54(3):395–404.

    Article  PubMed  Google Scholar 

  4. Yancey KB. Herpes gestationis. Dermatol Clin. 1990;8(4):727–35.

    CAS  PubMed  Google Scholar 

  5. Morrison LH, et al. Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen. J Clin Invest. 1988;81(6):2023–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Diaz LA, et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest. 1990;86(4):1088–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Karpati S, et al. Herpes gestationis: ultrastructural identification of the extracellular antigenic sites in diseased skin using immunogold techniques. Br J Dermatol. 1991;125(4):317–24.

    Article  CAS  PubMed  Google Scholar 

  8. Giudice GJ, et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol. 1993;151(10):5742–50.

    CAS  PubMed  Google Scholar 

  9. Carruthers JA, Ewins AR. Herpes gestationis: studies on the binding characteristics, activity and pathogenetic significance of the complement-fixing factor. Clin Exp Immunol. 1978;31(1):38–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Scheman AJ, et al. EVidence for eosinophil degranulation in the pathogenesis of herpes gestationis. Arch Dermatol. 1989;125(8):1079–83.

    Article  CAS  PubMed  Google Scholar 

  11. Kelly SE, Black MM. Pemphigoid gestationis: placental interactions. Semin Dermatol. 1989;8(1):12–7.

    CAS  PubMed  Google Scholar 

  12. Ortonne JP, et al. Herpes gestationis factor reacts with the amniotic epithelial basement membrane. Br J Dermatol. 1987;117(2):147–54.

    Article  CAS  PubMed  Google Scholar 

  13. Borthwick GM, Holmes RC, Stirrat GM. Abnormal expression of class II MHC antigens in placentae from patients with pemphigoid gestationis: analysis of class II MHC subregion product expression. Placenta. 1988;9(1):81–94.

    Article  CAS  PubMed  Google Scholar 

  14. Holmes RC, et al. A comparative study of toxic erythema of pregnancy and herpes gestationis. Br J Dermatol. 1982;106(5):499–510.

    Article  CAS  PubMed  Google Scholar 

  15. Lawley TJ, Stingl G, Katz SI. Fetal and maternal risk factors in herpes gestationis. Arch Dermatol. 1978;114(4):552–5.

    Article  CAS  PubMed  Google Scholar 

  16. Shornick JK, Black MM. Fetal risks in herpes gestationis. J Am Acad Dermatol. 1992;26(1):63–8.

    Article  CAS  PubMed  Google Scholar 

  17. Karna P, Broecker AH. Neonatal herpes gestationis. J Pediatr. 1991;119(2):299–301.

    Article  CAS  PubMed  Google Scholar 

  18. Holmes RC, Black MM. The fetal prognosis in pemphigoid gestationis (herpes gestationis). Br J Dermatol. 1984;110(1):67–72.

    Article  CAS  PubMed  Google Scholar 

  19. Al-Fares SI, Jones SV, Black MM. The specific dermatoses of pregnancy: a re-appraisal. J Eur Acad Dermatol Venereol. 2001;15(3):197–206.

    Article  CAS  PubMed  Google Scholar 

  20. Ponnighaus JM, Ziegler H, Kowalzick L. Herpes gestationis – oral corticosteroids cannot be avoided. Zentralbl Gynakol. 1998;120(11):548–50.

    CAS  PubMed  Google Scholar 

  21. Kroumpouzos G, Cohen LM. Specific dermatoses of pregnancy: an evidence-based systematic review. Am J Obstet Gynecol. 2003;188(4):1083–92.

    Article  PubMed  Google Scholar 

  22. Semkova K, Black M. Pemphigoid gestationis: current insights into pathogenesis and treatment. Eur J Obstet Gynecol Reprod Biol. 2009;145(2):138–44.

    Article  PubMed  Google Scholar 

  23. Kreuter A, et al. Intravenous immune globulin in the treatment of persistent pemphigoid gestationis. J Am Acad Dermatol. 2004;51(6):1027–8.

    Article  PubMed  Google Scholar 

  24. Hern S, et al. A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin. Clin Exp Dermatol. 1998;23(4):185–8.

    Article  CAS  PubMed  Google Scholar 

  25. Doiron P, Pratt M. Antepartum intravenous immunoglobulin therapy in refractory pemphigoid gestationis: case report and literature review. J Cutan Med Surg. 2010;14(4):189–92.

    Article  PubMed  Google Scholar 

  26. Sereno CFP, Marques-Gomes M, Cirne-Castro J. Refractory herpes gestationis responsive to intravenous immunoglobulin: a case report. J Am Acad Dermatol. 2005;52(3 Supplement):P116.

    Google Scholar 

  27. Roger D, et al. Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women. Arch Dermatol. 1994;130(6):734–9.

    Article  CAS  PubMed  Google Scholar 

  28. Ghazeeri G, Kibbi AG, Abbas O. Pruritic urticarial papules and plaques of pregnancy: epidemiological, clinical, and histopathological study of 18 cases from Lebanon. Int J Dermatol. 2012;51(9):1047–53.

    Article  PubMed  Google Scholar 

  29. Cohen LM, et al. Pruritic urticarial papules and plaques of pregnancy and its relationship to maternal-fetal weight gain and twin pregnancy. Arch Dermatol. 1989;125(11):1534–6.

    Article  CAS  PubMed  Google Scholar 

  30. Alcalay J, et al. Pruritic urticarial papules and plaques of pregnancy. A review of 21 cases. J Reprod Med. 1987;32(4):315–6.

    CAS  PubMed  Google Scholar 

  31. Aronson IK, et al. Pruritic urticarial papules and plaques of pregnancy: clinical and immunopathologic observations in 57 patients. J Am Acad Dermatol. 1998;39(6):933–9.

    Article  CAS  PubMed  Google Scholar 

  32. Petropoulou H, Georgala S, Katsambas AD. Polymorphic eruption of pregnancy. Int J Dermatol. 2006;45(6):642–8.

    Article  PubMed  Google Scholar 

  33. Beltrani VP, Beltrani VS. Pruritic urticarial papules and plaques of pregnancy: a severe case requiring early delivery for relief of symptoms. J Am Acad Dermatol. 1992;26(2):266–7.

    Article  CAS  PubMed  Google Scholar 

  34. Vaughan J, et al. A prospective study of 200 women with dermatoses of pregnancy correlating clinical findings with hormonal and immunopathological profiles. Br J Dermatol. 1999;141(1):71–81.

    Article  Google Scholar 

  35. Garcia-Gonzalez E, et al. Immunology of the cutaneous disorders of pregnancy. Int J Dermatol. 1999;38(10):721–9.

    Article  CAS  PubMed  Google Scholar 

  36. Dermatology, B., volume set/Jean L Bolognia [et al.]. editors: Jean L Bolognia, Joseph L Jorizzo, Ronald P Rapini. 2008, Elsevier Limited.

    Google Scholar 

  37. Glantz A, Marschall H-U, Mattsson L-Å. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology. 2004;40(2):467–74.

    Article  PubMed  Google Scholar 

  38. Lunzer MR. Jaundice in pregnancy. Baillieres Clin Gastroenterol. 1989;3(2):467–83.

    Article  CAS  PubMed  Google Scholar 

  39. Reyes H, et al. Steatorrhea in patients with intrahepatic cholestasis of pregnancy. Gastroenterology. 1987;93(3):584–90.

    Article  CAS  PubMed  Google Scholar 

  40. Bacq Y, et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology. 2012;143(6):1492–501.

    Article  CAS  PubMed  Google Scholar 

  41. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. 2004;5(3):266–71.

    Article  CAS  PubMed  Google Scholar 

  42. Doria A, et al. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol. 2006;22(2):234–41.

    Article  CAS  PubMed  Google Scholar 

Atopic Dermatitis

  1. Nedoszytko B, Sokołowska-Wojdyło M, Ruckemann-Dziurdzińska K, et al. Chemokines and cytokines network in the pathogenesis of the infammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis. Postepy Dermatol Alergol. 2014;2:84–91.

    Article  Google Scholar 

  2. Howell MD, et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity. 2006;24:341–8.

    Article  CAS  PubMed  Google Scholar 

  3. Giannetti A, Scarabello A, Miglietta S, Bassoli S. Atopic eczema or atopic dermatitis. Dermatol Sex Transm Dis. 2013;Chapter 51:969–71.

    Google Scholar 

  4. Rabenhorst A, Hartmann K. Interleukin-31: a novel diagnostic marker of allergic diseases. Curr Allergy Asthma Rep. 2014;14:423.

    Article  PubMed  CAS  Google Scholar 

  5. Stott B, Lavender P, Lehmann S, et al. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J Allergy Clin Immunol. 2013;132:446–54.

    Article  CAS  PubMed  Google Scholar 

  6. Auriemma M, Vianale G, Amerio P, et al. Cytokines and T cells in atopic dermatitis. Eur Cytokine Netw. 2013;24:37–44.

    CAS  PubMed  Google Scholar 

  7. Novak N. An update on the role of human dendritic cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2012;129:879–86.

    Article  CAS  PubMed  Google Scholar 

  8. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–94.

    Article  CAS  PubMed  Google Scholar 

  9. Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2:e24137.

    PubMed  PubMed Central  Google Scholar 

  10. Cheung PF, Wong CK, Ho AW, et al. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. 2010;22:453–67.

    Article  CAS  PubMed  Google Scholar 

  11. Angel CE, George E, Brooks AE, Ostrovsky LL, Brown TL, Dunbar PR. Cuttingedge: CD1a1 antigen-presenting cells in human dermis respond rapidly to CCR7 ligands. J Immunol. 2006;176:5730–4.

    Article  CAS  PubMed  Google Scholar 

  12. Kopfnagel V, Harder J, Werfel T. Expression of antimicrobial peptides in atopic dermatitis and possible immunoregulatory functions. Curr Opin Allergy Clin Immunol. 2013;13:531–6.

    Article  CAS  PubMed  Google Scholar 

  13. Han NR, Oh HA, Nam SY, Moon PD, Kim DW, Kim HM, Jeong HJ. TSLP induces mast cell development and aggravates allergic reactions through the activation of MDM2 and STAT6. J Invest Dermatol. 2014;134(10):2521–30.

    Article  CAS  PubMed  Google Scholar 

  14. Suárez-Fariñas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132:361–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Mu Z, Zhao Y, Liu X, et al. Molecular biology of atopic dermatitis. Clin Rev Allerg Immunol. 2014;47:193–218.

    Article  CAS  Google Scholar 

  16. Zhang H, Guo YF, Wang WZ, et al. Mutations in the filaggrin gene in Han Chinese patients with atopic dermatitis. Allergy. 2011;66:420–7.

    Article  CAS  PubMed  Google Scholar 

  17. Li M, Liu Q, Liu JB, et al. Mutations analysis in filaggrin gene in northern China patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2013;27(2):169–74.

    Article  CAS  PubMed  Google Scholar 

  18. Cheng R, Li M, Zhang H, et al. Common FLG mutation K4671X not associated with atopic dermatitis in Han Chinese in a family association study. PLoS One. 2012;7(11):e49158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134:792–9.

    Article  CAS  PubMed  Google Scholar 

  20. Melnik BC. The potential role of impaired notch signalling in atopic dermatitis. Acta Derm Venereol. 2015;95:5–11.

    Article  CAS  PubMed  Google Scholar 

  21. Buddenkotte J, Steinhoff M. Pathophysiology and therapy of pruritus in allergic and atopic diseases. Allergy. 2010;65:805–21.

    Article  CAS  PubMed  Google Scholar 

  22. Wilson SR, The L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013;155:285–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Paraneoplastic Dermatoses

  1. Silva JA, Mesquita Kde C, Igreja AC, et al. Paraneoplastic cutaneous manifestations: concepts and updates. An Bras Dermatol. 2013;88:9–22.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Outerbridge CA. Cutaneous manifestations of internal diseases. Vet Clin North Am. 2013;43:135–52.

    Article  Google Scholar 

  3. Ehst BD, Minzer-Conzetti K, Swerdlin A, Devere TS. Cutaneous manifestations of internal malignancy. Curr Probl Surg. 2010;47:384–445.

    Article  PubMed  Google Scholar 

  4. Pipkin CA, Lio PA. Cutaneous manifestations of internal malignancies: an overview. Dermatol Clin. 2008;26:1–15, vii.

    Article  CAS  PubMed  Google Scholar 

  5. Brenner S, Tamir E, Maharshak N, Shapira J. Cutaneous manifestations of internal malignancies. Clin Dermatol. 2001;19:290–7.

    Article  CAS  PubMed  Google Scholar 

  6. Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS. The etiology of paraneoplastic autoimmunity. Clin Rev Allergy Immunol. 2012;42:135–44.

    Article  CAS  PubMed  Google Scholar 

  7. Braverman IM. Skin manifestations of internal malignancy. Clin Geriatr Med. 2002;18:1–19, v.

    Article  PubMed  Google Scholar 

  8. Chung VQ, Moschella SL, Zembowicz A, Liu V. Clinical and pathologic findings of paraneoplastic dermatoses. J Am Acad Dermatol. 2006;54:745–62; quiz 63–6.

    Article  PubMed  Google Scholar 

  9. Thomas I, Schwartz RA. Cutaneous paraneoplastic syndromes: uncommon presentations. Clin Dermatol. 2005;23:593–600.

    Article  PubMed  Google Scholar 

  10. Ramos ESM, Carvalho JC, Carneiro SC. Cutaneous paraneoplasia. Clin Dermatol. 2011;29:541–7.

    Article  Google Scholar 

  11. Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatol Online J. 2008;14:2.

    PubMed  Google Scholar 

  12. Krawczyk M, Mykala-Ciesla J, Kolodziej-Jaskula A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn. 2009;119:180–3.

    PubMed  Google Scholar 

  13. Thiers BH, Sahn RE, Callen JP. Cutaneous manifestations of internal malignancy. CA Cancer J Clin. 2009;59:73–98.

    Article  PubMed  Google Scholar 

  14. Cohen PR, Grossman ME, Almeida L, Kurzrock R. Tripe palms and malignancy. J Clin Oncol. 1989;7:669–78.

    Article  CAS  PubMed  Google Scholar 

  15. Cohen PR, Grossman ME, Silvers DN, Kurzrock R. Tripe palms and cancer. Clin Dermatol. 1993;11:165–73.

    Article  CAS  PubMed  Google Scholar 

  16. Moore RL, Devere TS. Epidermal manifestations of internal malignancy. Dermatol Clin. 2008;26:17–29, vii.

    Article  CAS  PubMed  Google Scholar 

  17. Shah KR, Boland CR, Patel M, Thrash B, Menter A. Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol. 2013;68:189 e1-21; quiz 210.

    Article  PubMed  Google Scholar 

  18. Yeh JS, Munn SE, Plunkett TA, Harper PG, Hopster DJ, du Vivier AW. Coexistence of acanthosis nigricans and the sign of Leser-Trelat in a patient with gastric adenocarcinoma: a case report and literature review. J Am Acad Dermatol. 2000;42:357–62.

    Article  CAS  PubMed  Google Scholar 

  19. Schwartz RA. Sign of Leser-Trelat. J Am Acad Dermatol. 1996;35:88–95.

    Article  CAS  PubMed  Google Scholar 

  20. Joseph JV, Turner KJ, Bramwell SP. Dermatomyositis: a rare initial presentation of adenocarcinoma of the prostate. J Urol. 2002;168:637.

    Article  CAS  PubMed  Google Scholar 

  21. Stone SP, Buescher LS. Life-threatening paraneoplastic cutaneous syndromes. Clin Dermatol. 2005;23:301–6.

    Article  PubMed  Google Scholar 

  22. Boyd AS, Neldner KH, Menter A. Erythema gyratum repens: a paraneoplastic eruption. J Am Acad Dermatol. 1992;26:757–62.

    Article  CAS  PubMed  Google Scholar 

  23. Eubanks LE, McBurney E, Reed R. Erythema gyratum repens. Am J Med Sci. 2001;321:302–5.

    Article  CAS  PubMed  Google Scholar 

  24. Tyring SK. Reactive erythemas: erythema annulare centrifugum and erythema gyratum repens. Clin Dermatol. 1993;11:135–9.

    Article  CAS  PubMed  Google Scholar 

  25. Adam DN, Cohen PD, Ghazarian D. Necrolytic migratory erythema: case report and clinical review. J Cutan Med Surg. 2003;7:333–8.

    Article  PubMed  Google Scholar 

  26. Geria AN, Holcomb KZ, Scheinfeld NS. Necrolytic acral erythema: a review of the literature. Cutis. 2009;83:309–14.

    PubMed  Google Scholar 

  27. van Beek AP, de Haas ER, van Vloten WA, Lips CJ, Roijers JF, Canninga-van Dijk MR. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151:531–7.

    Article  PubMed  Google Scholar 

  28. Tierney EP, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. MedGenMed. 2004;6:4.

    PubMed  PubMed Central  Google Scholar 

  29. Valdivielso M, Longo I, Suarez R, Huerta M, Lazaro P. Acrokeratosis paraneoplastica: Bazex syndrome. J Eur Acad Dermatol Venereol. 2005;19:340–4.

    Article  CAS  PubMed  Google Scholar 

  30. Bolognia JL, Brewer YP, Cooper DL. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine (Baltimore). 1991;70:269–80.

    Article  CAS  Google Scholar 

  31. Rao R, Shenoi SD. Acrokeratosis paraneoplastica (Bazex syndrome): an atypical presentation. Dermatol Online J. 2004;10:21.

    PubMed  Google Scholar 

  32. Sharma V, Sharma NL, Ranjan N, Tegta GR, Sarin S. Acrokeratosis paraneoplastica (Bazex syndrome): case report and review of literature. Dermatol Online J. 2006;12:11.

    PubMed  Google Scholar 

  33. Zarzour JG, Singh S, Andea A, Cafardi JA. Acrokeratosis paraneoplastica (Bazex syndrome): report of a case associated with small cell lung carcinoma and review of the literature. J Radiol Case Rep. 2011;5:1–6.

    PubMed  PubMed Central  Google Scholar 

  34. Abreu Velez AM, Howard MS. Diagnosis and treatment of cutaneous paraneoplastic disorders. Dermatol Ther. 2010;23:662–75.

    Article  PubMed  Google Scholar 

  35. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323:1729–35.

    Article  CAS  PubMed  Google Scholar 

  36. Yong AA, Tey HL. Paraneoplastic pemphigus. Australas J Dermatol. 2013;54:241–50.

    Article  PubMed  Google Scholar 

  37. Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med. 1999;340:1406–10.

    Article  CAS  PubMed  Google Scholar 

  38. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol. 1993;129:883–6.

    Article  CAS  PubMed  Google Scholar 

  39. Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin. 2011;29:419–25, viii.

    Article  CAS  PubMed  Google Scholar 

  40. Wang L, Bu D, Yang Y, Chen X, Zhu X. Castleman’s tumours and production of autoantibody in paraneoplastic pemphigus. Lancet. 2004;363:525–31.

    Article  CAS  PubMed  Google Scholar 

  41. Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges. 2010;8:598–606.

    PubMed  Google Scholar 

  42. Frew JW, Murrell DF. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome). Dermatol Clin. 2011;29:607–12.

    Article  CAS  PubMed  Google Scholar 

  43. Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol. 2009;48:162–9.

    Article  PubMed  Google Scholar 

  44. Wang J, Zhu X, Li R, et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol. 2005;141:1285–93.

    PubMed  Google Scholar 

  45. Iorizzo 3rd LJ, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol. 2008;59:99–112.

    Article  PubMed  Google Scholar 

  46. Smith ES, Hallman JR, DeLuca AM, Goldenberg G, Jorizzo JL, Sangueza OP. Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol. 2009;31:61–7.

    Article  PubMed  Google Scholar 

  47. Iaccarino L, Ghirardello A, Bettio S, et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun. 2014;48–49:122–7.

    Article  PubMed  CAS  Google Scholar 

  48. Zaba LC, Fiorentino DF. Skin disease in dermatomyositis. Curr Opin Rheumatol. 2012;24:597–601.

    Article  PubMed  Google Scholar 

  49. Strowd LC, Jorizzo JL. Review of dermatomyositis: establishing the diagnosis and treatment algorithm. J Dermatolog Treat. 2013;24:418–21.

    Article  PubMed  Google Scholar 

  50. Femia AN, Vleugels RA, Callen JP. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol. 2013;14:291–313.

    Article  PubMed  Google Scholar 

  51. Ungprasert P, Bethina NK, Jones CH. Malignancy and idiopathic inflammatory myopathies. N Am J Med Sci. 2013;5:569–72.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012;8:CD003643.

    Google Scholar 

Graft-Versus-Host Skin Disease

  1. Johnson ML, et al. Graft-versus-host reactions in dermatology. J Am Acad Dermatol. 1998;38(3):369–92.

    Article  CAS  PubMed  Google Scholar 

  2. Yasunori I, et al. T cell immunity and graft-versus-host disease (GVHD). Autoimmun Rev. 2006;5:1–9.

    Article  Google Scholar 

  3. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21–78.

    PubMed  Google Scholar 

  4. Leitman SF, Holland PV. Irradiation of blood products: indications and guidelines. Transfusion. 1985;25:293–300.

    Article  CAS  PubMed  Google Scholar 

  5. Alexander G, Portman B. Graft-versus-host disease after liver transplantation. Hepatology. 1990;11:144–5.

    Article  CAS  PubMed  Google Scholar 

  6. Joysey VC, Wood H, Ramsbottom S, Morgan H, Ford C, Horsford J, et al. Lymphocyte chimerism after organ transplantation. Transplant Proc. 1992;24:2519–22.

    CAS  PubMed  Google Scholar 

  7. Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2012;66(4):515.e1-18; quiz 533–4.

    Article  PubMed  Google Scholar 

  8. Petersdorf EW. Genetics of graft-versus-host disease: the major histocompatibility complex. Blood Rev. 2013;27(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  9. Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL, et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLAmatched unrelated donors. N Engl J Med. 1990;322:485–94.

    Article  CAS  PubMed  Google Scholar 

  10. Elkins WL. Cellular immunology and the pathogenesis of graft-versus-host reactions. Prog Allergy. 1971;15:78–187.

    CAS  PubMed  Google Scholar 

  11. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765–71.

    Article  CAS  PubMed  Google Scholar 

  12. Beatty PG, Hansen JA, Anasetti C, Sanders J, Buckner CD, Storb R, et al. Marrow transplantation from unrelated HLA-matched volunteer donors. Transplant Proc. 1989;21:2993–4.

    CAS  PubMed  Google Scholar 

  13. Witherspoon RP, Deeg HJ, Storb R. Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplant Sci. 1994;4:33–41.

    CAS  PubMed  Google Scholar 

  14. Toubai T, Tawara I, Sun YP, et al. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood. 2012;119(16):3844–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Martin PJ. Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors. Bone Marrow Transplant. 1991;8:217–23.

    CAS  PubMed  Google Scholar 

  16. Hahn T, McCarthy Jr PL, Zhang MJ, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008;26(35):5728–34.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev. 1985;88:215–38.

    Article  CAS  PubMed  Google Scholar 

  18. Klingeman HG, Storb R, Fefer A, Deeg HG, Appelbaum FR, Buckner CD, et al. Bone marrow transplantation in patients aged 45 years and older. Blood. 1986;67:770–6.

    Google Scholar 

  19. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsey N, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991;51:1197–203.

    Article  CAS  PubMed  Google Scholar 

  20. Randolph SS, Gooley TA, Warren EH, et al. Female donors contribute to a seslective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103(1):347–52.

    Article  CAS  PubMed  Google Scholar 

  21. Michallet M, Corront B, Bosson JL, Reiffers J, Marit G, Maraninchi D, et al. Risk factors for GVHD: study of 157 patients from Bordeaux, Grenoble, Marseille. Bone Marrow Transplant. 1988;3 Suppl 1:226.

    Google Scholar 

  22. Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987;67:397–406.

    Article  CAS  PubMed  Google Scholar 

  23. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.

    Article  PubMed  Google Scholar 

  24. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008;14:236–45.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ferrara JL, Levine JE, Reddy P, Holler E. Graftversus-host disease. Lancet. 2009;373:1550–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hausermann P, Walter RB, Halter J, Biedermann BC, Tichelli A, Itin P, et al. Cutaneous graft-versushost disease: a guide for the dermatologist. Dermatology. 2008;216:287–304.

    Article  PubMed  Google Scholar 

  27. Friedman KJ, LeBoit PE, Farmer ER. Acute follicular graft-vs-host reaction. A distinct clinicopathologic presentation. Arch Dermatol. 1988;124:688–91.

    Article  CAS  PubMed  Google Scholar 

  28. Marra DE, McKee PH, Nghiem P. Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. J Am Acad Dermatol. 2004;51:543–6.

    Article  PubMed  Google Scholar 

  29. Hymes SR, Farmer ER, Lewis PG, Tutschka PJ, Santos GW. Cutaneous graft-versus-host reaction: prognostic features seen by light microscopy. J Am Acad Dermatol. 1985;12:468–74.

    Article  CAS  PubMed  Google Scholar 

  30. Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc. 1974;6:367–71.

    CAS  PubMed  Google Scholar 

  31. Lee SJ. Have we made progress in the management of chronic graft-vs-host disease? Best Pract Res Clin Haematol. 2010;23:529–35.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008;2008:134–41.

    Google Scholar 

  33. Beers B, Kalish RS, Kaye VN, Dahl MV. Unilateral linear lichenoid eruption after bone marrow transplantation: an unmasking of tolerance to an abnormal keratinocyte clone? J Am Acad Dermatol. 1993;28:888–92.

    Article  CAS  PubMed  Google Scholar 

  34. Schauder CS, Hymes SR, Rapini RP, Zipf TF. Vesicular graftversus-host disease. Int J Dermatol. 1992;31:509–10.

    Article  CAS  PubMed  Google Scholar 

  35. Aractingi S, Janin A, Devergie A, Bourges M, Socie G, Gluckman E. Histochemical and ultrastructural study of diffuse melanoderma after bone marrow transplantation. Br J Dermatol. 1996;134:325–31.

    Article  CAS  PubMed  Google Scholar 

  36. Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biol Blood Marrow Transplant. 2006;12:252–66.

    Article  PubMed  Google Scholar 

  37. Kroft EB, Berkhof NJ, van de Kerkhof PC, Gerritsen RM, de Jong EM. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol. 2008;59:1017–30.

    Article  PubMed  Google Scholar 

  38. Clark J, Yao L, Pavletic SZ, Krumlauf M, Mitchell S, Turner ML, et al. Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease. Arch Dermatol. 2009;145:918–22.

    Article  PubMed  Google Scholar 

  39. Penas PF, Jones-Caballero M, Aragues M, Fernandez-Herrera J, Fraga J, Garcia-Diez A. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol. 2002;138:924–34.

    Article  PubMed  Google Scholar 

  40. Hymes SR, Turner ML, Champlin RE, Couriel DR. Cutaneous manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12(11):1101–13.

    Article  PubMed  Google Scholar 

  41. Wei J, Zhang Y, Xu HJ, Jin J, Zhang JZ. Atopic dermatitiselike presentation of graft-versus-host disease: a novel form of chronic cutaneous graft-versus-host disease. J Am Acad Dermatol. 2013;69:34–9.

    Article  PubMed  Google Scholar 

  42. Sanli H, Arat M, Oskay T, Gurman G. Evaluation of nail involvement in patients with chronic cutaneous graft versus host disease: a single-center study from Turkey. Int J Dermatol. 2004;43:176–80.

    Article  PubMed  Google Scholar 

  43. Sullivan KM, Shulman HM, Storb R, et al. Chronic graftversus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267–76.

    CAS  PubMed  Google Scholar 

  44. Carpenter PA. How I conduct a comprehensive chronic graft-versus host disease assessment. Blood. 2011;118:2679–87.

    Article  CAS  PubMed  Google Scholar 

  45. Spinelli S, Chiodi S, Costantini S, et al. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica. 2003;88:1163–8.

    PubMed  Google Scholar 

  46. Hymes SR, Farmer ER, Burns WH, et al. Bullous sclerodermalike changes in chronic graft-vs-host disease. Arch Dermatol. 1985;121:1189–92.

    Article  CAS  PubMed  Google Scholar 

  47. Patel AR, Turner ML, Baird K, Gea-Banacloche J, Mitchell S, Pavletic SZ, et al. Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2009;15:370–6.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Wu PA, Cowen EW. Cutaneous graft-versus-host disease-clinical considerations and management. Curr Probl Dermatol. 2012;43:101–15.

    Article  PubMed  Google Scholar 

  49. Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010;16:1611–28.

    Article  PubMed  Google Scholar 

  50. Mielcarek M, Storer BE, Boeckh M, Carpenter PA, McDonald GB, Deeg HJ, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113:2888–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Penas PF, Fernandez-Herrera J, Garcia-Diez A. Dermatologic treatment of cutaneous graft versus host disease. Am J Clin Dermatol. 2004;5:403–16.

    Article  PubMed  Google Scholar 

  52. Vogelsang GB. How I treat chronic graft-versushost disease. Blood. 2001;97:1196–201.

    Article  CAS  PubMed  Google Scholar 

  53. Rossi SJ, Schroeder TJ, Hariharan S, First MR. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf. 1993;9:104–31.

    Article  CAS  PubMed  Google Scholar 

  54. Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease. J Am Acad Dermatol. 2012;66(4):535.e1-16.

    Article  PubMed  Google Scholar 

  55. Gilman AL, Chan KW, Mogul A, Morris C, Goldman FD, Boyer M, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:327–34.

    Article  CAS  PubMed  Google Scholar 

  56. Ziegler HK, Unanue ER. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A. 1982;79:175–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graftversus-host disease and disease remission. Blood. 2005;105:2973–8.

    Article  CAS  PubMed  Google Scholar 

  58. Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004;103:353–9.

    Article  CAS  PubMed  Google Scholar 

  59. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graftversus-host disease: a systematic review and metaanalysis. Biol Blood Marrow Transplant. 2009;15:1005–13.

    Article  CAS  PubMed  Google Scholar 

  60. Moreno-Romero JA, Fernandez-Aviles F, Carreras E, Rovira M, Martinez C, Mascaro Jr JM. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease. Arch Dermatol. 2008;144:1106–9.

    Article  CAS  PubMed  Google Scholar 

  61. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114:709–18.

    Article  CAS  PubMed  Google Scholar 

  62. Parker PM, Chao N, Nademanee A, O’Donnell MR, Schmidt GM, Snyder DS, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995;86:3604–9.

    CAS  PubMed  Google Scholar 

  63. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood. 2000;96:3995–6.

    CAS  PubMed  Google Scholar 

  64. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11–20.

    Article  PubMed  Google Scholar 

  65. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389–97.

    Article  CAS  PubMed  Google Scholar 

  66. Ringden O, Le Blanc K. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract Res Clin Haematol. 2011;24:65–72.

    Article  CAS  PubMed  Google Scholar 

  67. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.

    Article  PubMed  CAS  Google Scholar 

  68. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010;45:1732–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y, et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant. 2010;16:403–12.

    Article  CAS  PubMed  Google Scholar 

  70. Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17:1–17.

    Article  PubMed  Google Scholar 

  71. Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol. 2001;137:1202–6.

    Article  CAS  PubMed  Google Scholar 

  72. Riemens A, te Boome L, Imhof S, Kuball J, Rothova A. Current insights into ocular graft-versus-host disease. Curr Opin Ophthalmol. 2010;21:485–94.

    Article  PubMed  Google Scholar 

  73. Ziemer M, Gruhn B, Thiele JJ, Elsner P. Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus. J Am Acad Dermatol. 2004;50:946–8.

    Article  PubMed  Google Scholar 

  74. Prot-Labarthe S, Therrien R, Champagne MA, Duval M, Joubert C. Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease. Bone Marrow Transplant. 2007;40:295–6.

    Article  CAS  PubMed  Google Scholar 

  75. Cowen EW, Nguyen JC, Miller DD, McShane D, Arron ST, Prose NS, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol. 2010;62:31–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of California San Francisco, San Francisco, CA, USA

    Melissa Danesh BS & Jenny E. Murase MD

  2. Department of Dermatology, Palo Alto Foundation Medical Group, 701 East El Camino Real (31-104), Mountain View, CA, 94040, USA

    Jenny E. Murase MD

  3. Department of Dermatology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shenyang, China

    Zhirong Yao, Ruhong Cheng & Huaguo Li

  4. Sun Yat-Sen Hospital, Guangzhou, China

    Liangchun Wang

  5. Department of Dermatology, Peking University People’s Hospital, Beijing, 100044, China

    Jian-Zhong Zhang & Jin Wei

Authors
  1. Melissa Danesh BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jenny E. Murase MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhirong Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ruhong Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Huaguo Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liangchun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jian-Zhong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jin Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jenny E. Murase MD , Zhirong Yao , Liangchun Wang , Jian-Zhong Zhang , Jenny E. Murase MD , Zhirong Yao , Liangchun Wang or Jian-Zhong Zhang .

Editor information

Editors and Affiliations

  1. Dermatology, The first affiliated Hospital China Medical University, Shenyang, China

    Xing-Hua Gao

  2. Dermatology, The first affiliated Hospital China Medical University, Shenyang, China

    Hong-Duo Chen

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Danesh, M. et al. (2017). Diseases with Underlining Internal Conditions. In: Gao, XH., Chen, HD. (eds) Practical Immunodermatology. Springer, Dordrecht. https://doi.org/10.1007/978-94-024-0902-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-94-024-0902-4_9

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-024-0900-0

  • Online ISBN: 978-94-024-0902-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation